18F-Fluorodeoxyglucose-positron emission tomography/computed tomography in Lymphoma

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• FDG-PET/CT is integral to staging, response assessment (Deauville score), and prognosis in Hodgkin and non-Hodgkin lymphomas.
• Quantitative metrics like total metabolic tumor volume are potent prognostic biomarkers.

Purpose of the Study:

• To review the role of FDG-PET/CT in lymphoma management.
• To highlight emerging quantitative and AI-driven approaches for prognostication and response assessment.

Main Methods:

• Review of current literature on FDG-PET/CT applications in lymphoma.
• Discussion of interim PET utility in Hodgkin lymphoma and DLBCL.
• Exploration of CAR-T therapy monitoring and bridging therapy guidance.
• Consideration of PET radiomics and deep learning for future applications.

Main Results:

• Interim PET guides treatment de-escalation in Hodgkin lymphoma but is only prognostic in DLBCL.
• FDG-PET/CT serves as a prognostic biomarker during CAR-T therapy and for bridging therapy decisions.
• Quantitative PET metrics are independent prognostic factors.

Conclusions:

• FDG-PET/CT is a versatile tool in lymphoma diagnosis, staging, and response evaluation.
• Emerging PET-based radiomics and deep learning methods require standardization for advanced prognostication and response assessment in the era of targeted therapies.